Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis

Digestive and Liver Disease

Volumn 44, Issue 4, 2012, Pages 334-342

  Salamone, Federico ^a   Galvano, Fabio ^a   Marino, Antonella ^b   Paternostro, Claudia ^c   Tibullo, Daniele ^a   Bucchieri, Fabio ^b,d   Mangiameli, Andrea ^a   Parola, Maurizio ^c   Bugianesi, Elisabetta ^e   Li Volti, Giovanni ^a,f  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Istituto EuroMediterraneo di Scienza e Tecnologia   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f San Donato Institute   (Italy)

Author keywords

Heart; Inflammation; NAFLD; Oxidative stress; Silibinin

Indexed keywords

8 DEOXYGUANOSINE; ALANINE AMINOTRANSFERASE; CHOLINE; CYTOKINE; GLUTATHIONE; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; METHIONINE; NITRATE; NITRITE; SILIBININ; SILIBININ DIHYDROGEN SUCCINATE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIETARY INTAKE; DRUG EFFECT; ENZYME PHOSPHORYLATION; HEART MUSCLE INJURY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER INJURY; LIVER MITOCHONDRION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY CHAIN; TREATMENT DURATION;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; CHOLINE DEFICIENCY; CYTOKINES; DIET; FATTY LIVER; GENE EXPRESSION; GLUTATHIONE; INSULIN RESISTANCE; ISOPROSTANES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; MALE; METHIONINE; MICE; MYOCARDIUM; NITRATES; NITRITES; OXIDATIVE STRESS; PHOSPHORYLATION; SILYMARIN; STATISTICS, NONPARAMETRIC;

EID: 84857656203     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.11.010     Document Type: Article

References (48)

1. Musso G., Gambino R., Cassader M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2010, [epub ahead of print].
2. Brunt E.M. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009, 13:533-544.
3. Korenblat K.M., Fabbrini E., Mohammed B.S., et al. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134:1369-1375.
4. Fabbrini E., Magkos F., Mohammed B.S., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009, 106:15430-15435.
5. Salamone F., Bugianesi E. Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome. J Hepatol 2011, 53:1146-1147.
6. Speliotes E.K., Massaro J.M., Hoffmann U., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51:1979-1987.
7. Salamone F., Galvano F., Li Volti G. Treating fatty liver for the prevention of cardiovascular diseases. Hepatology 2010, 52:1174-1175.
8. Lautamaki R., Borra R., Iozzo P., et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006, 291:E282-E290.
9. McGavock J.M., Victor R.G., Unger R.H., et al. Adiposity of the heart, revisited. Ann Intern Med 2006, 144:517-524.
10. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
11. Perseghin G., Lattuada G., De Cobelli F., et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008, 47:51-58.
12. Trauner M., Arrese M., Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010, 1801:299-310.
13. Mantena S.K., King A.L., Andringa K.K., et al. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008, 44:1259-1272.
14. Marra F. Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy. Gut 2008, 57:570-572.
15. Videla L.A., Tapia G., Rodrigo R., et al. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) 2009, 17:973-979.
16. Brindley D.N., Kok B.P., Kienesberger P.C., et al. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab 2010, 298:E897-E908.
17. Mellor K.M., Ritchie R.H., Delbridge L.M. Reactive oxygen species and insulin-resistant cardiomyopathy. Clin Exp Pharmacol Physiol 2010, 37:222-228.
18. Mira L., Silva M., Manso C.F. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994, 48:753-759.
19. Dehmlow C., Erhard J., de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996, 23:749-754.
20. Pietrangelo A., Borella F., Casalgrandi G., et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995, 109:1941-1949.
21. Crocenzi F.A., Sanchez Pozzi E.J., Pellegrino J.M., et al. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology 2001, 34:329-339.
22. Schumann J., Prockl J., Kiemer A.K., et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003, 39:333-340.
23. Sahai A., Malladi P., Pan X., et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004, 287:G1035-G1043.
24. Rinella M.E., Elias M.S., Smolak R.R., et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008, 49:1068-1076.
25. Vizzutti F., Provenzano A., Galastri S., et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest 2010, 90:104-115.
26. Videla L.A., Rodrigo R., Orellana M., et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004, 106:261-268.
27. Serviddio G., Bellanti F., Tamborra R., et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 2008, 57:957-965.
28. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
29. Halliwell B., Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br J Pharmacol 2004, 142:231-255.
30. Seki S., Kitada T., Yamada T., et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002, 37:56-62.
31. Kidd P., Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005, 10:193-203.
32. Ferenci P., Scherzer T.M., Kerschner H., et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008, 135:1561-1567.
33. Bares J.M., Berger J., Nelson J.E., et al. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol 2008, 42:937-944.
34. Federico A., Trappoliere M., Tuccillo C., et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006, 55:901-902.
35. Trappoliere M., Caligiuri A., Schmid M., et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol 2009, 50:1102-1111.
36. Caballero F., Fernandez A., Matias N., et al. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-l-methionine and glutathione. J Biol Chem 2010, 285:18528-18536.
37. Wei Y., Rector R.S., Thyfault J.P., et al. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008, 14:193-199.
38. Rector R.S., Thyfault J.P., Uptergrove G.M., et al. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010, 52:727-736.
39. Serviddio G., Bellanti F., Giudetti A.M., et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther 2010, 332:922-932.
40. Han D., Ybanez M.D., Ahmadi S., et al. Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal 2009, 11:2245-2263.
41. Khaper N., Bryan S., Dhingra S., et al. Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. Antioxid Redox Signal 2010, 13:1033-1034.
42. Garcia-Ruiz I., Rodriguez-Juan C., Diaz-Sanjuan T., et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 2006, 44:581-591.
43. Petersen A.M., Pedersen B.K. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006, 57(Suppl. 10):43-51.
44. Hong F., Radaeva S., Pan H.N., et al. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004, 40:933-941.
45. Sánchez-Garrido M.A., Chico Y., González R., et al. Interleukin-6 is associated with liver lipid homeostasis but not with cell death in experimental hepatic steatosis. Innate Immun 2009, 15:337-349.
46. Chabowski A., Zmijewska M., Górski J., et al. Effect of IL-6 deficiency on myocardial expression of fatty acid transporters and intracellular lipid deposits. J Physiol Pharmacol 2007, 58:73-82.
47. Kassel K.M., Guo G.L., Tawfik O., et al. Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet. Lab Invest 2010, 90:1794-1804.
48. Svegliati-Baroni G., Candelaresi C., Saccomanno S., et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006, 169:846-860.